Background: Tigecycline resistance has emerged recently and has shown diverse mechanisms. The aim of this study was to assess the role of efflux activity in tigecycline resistance in 120 clinical isolates of A. baumannii using two methods: the H33342 accumulation assay and adeB real-time reverse transcriptase polymerase chain reaction. In addition, we analyzed the correlation between the expression level of adeB and H33342 accumulation level. Methods: A. baumannii clinical isolates was divided into tigecycline-resistant (49 strains), intermediate (40 strains), and susceptible (31 strains) groups. The H33342 accumulation was measured in the absence or presence of the efflux pump inhibitor carbonyl cyanide 3-chlorophenylhydrazone (CCCP). Real-time RT-PCR was performed to determine the relative expression of the adeB gene in A. baumannii clinical isolates.
INTRODUCTION
Acinetobacter baumannii has successfully become a significant nosocomial agent worldwide, essentially because of its ability to survive in the hospital environment, and its propensity to rapidly acquire antibiotic resistance mechanisms [1] . In addition to its high capacity to acquire new genetic determinants, overproduction of efflux pumps with broad substrate specificity has been shown to be associated with multidrug resistance (MDR) in A. baumannii [2, 3] . The resistance-nodulation-cell division (RND) systems are the most prevalent efflux pump systems in multidrug-resistant A. baumannii. Among three RND type efflux pumps, overexpression of AdeABC constitutes a major mechanism of multiresistance in A. baumannii [2] .
Tigecycline, a glycylcycline antibiotic, retains activity against a broad range of both gram-positive and gram-negative bacteria that includes methicillin-resistant Staphylococcus, vancomycinresistant Enterococcus, and A. baumannii multidrug-resistant isolates [4] . However, tigecycline resistance in A. baumannii has emerged recently. It is reported that tigecycline nonsusceptibility in A. baumannii isolates has been associated with overexpression of a variety of efflux pumps. Among them, the active efflux pump AdeABC appeared to play important roles in the tigecycline resistance of A. baumannii [5] .
Rapid assessment of efflux pump activity is important because increased expression of chromosomal genes for efflux systems plays a major role in multidrug resistance (MDR) [2] .
Fluorescent dyes, such as ethidium bromide and the bis-benzamide dye Hoechst 33342 (H33342), are substrates of efflux pump systems, and can act as reporters of efflux activity. The H33342 accumulation assay is a cheap, relatively rapid, sensitive and specific test for MDR [6] . It has been used for the assessment of cellular permeability and efflux activity in Salmonella enterica and Escherichia coli [6, 7] . H33342 accumulation has also been used in A. baumannii to assess the contribution of efflux activity to antibiotic accumulation [8, 9] .
Addition of the efflux pump inhibitor, carbonyl cyanide 3-chlorophenylhydrazone (CCCP), which dissipates the proton motive force required by several efflux pumps, causes a significant increase in H33342 accumulation, suggesting reduced efflux pump activity due to the inhibition of active efflux [9] . Although it was used effectively to assess efflux activity between several strains of bacteria including S. enterica, E. coli and A. baumannii [6, 9] , it is hard to find out studies using it as an assessing tool of efflux activity in a lot of clinical strains of A.
baumannii.
In this study, we assessed the role of the efflux system using 
MATERIALS AND METHODS

Bacterial isolates and growth conditions
A total of 120 A. baumannii clinical isolates were collected from January 2012 to December 2015 at Chosun University Hospital for use in this study. Bacterial identification was performed using the VITEK 2 system (bioMérieux, Marcy l'Etoile, France). Thereafter, species identification was confirmed by gyrB multiplex PCR and blaOXA-51-like PCR [10, 11] . Antimicrobial susceptibility for tigecycline was also determined using the 
H33342 accumulation assay
The H33342 accumulation assay was carried out as described by Richmond et al. [9] , with the following modifications. For the rpoB gene, we used rpoB-for-1 (5′-ctcactatggtcgtgtttgtc-3′) and rpoB-rev-2 (5′-ccaagaaaccgaagtcattcg-3′). The normalized expression of adeB was calibrated using the expression of A. baumannii ATCC 19606, which was assigned a value of 1.0.
All experiments were performed in triplicate. We considered a threshold cycle (Ct; the lowest cycle number to produce a detectable fluorescent signal) value of 38 as the cut-off for a negative result in real-time PCR [12] .
Statistical analysis
Statistical differences between each comparison group were determined using Student's t-test in the H33342 accumulation assay and adeB relative expression analysis. SPSS statistics 21 program (IBM Corp., Armonk, NY, USA) was used for the statistical analyses. P values of ＜0.05 were considered statistically significant.
RESULTS
To determine the appropriate time to measure H33342 accumulation, we observed the change in level over the time period ATCC 19606 and both tigecycline-susceptible strains was higher than that of the three resistant strains at steady-state (Fig. 1A) .
The addition of CCCP, an efflux pump inhibitor, caused a significant increase in the level of H33342 accumulation only in the tigecycline-resistant strains. The fold change in H33342 accumulation between the presence of CCCP and the absence of CCCP was lower in the tigecycline-susceptible isolates (15136S and 15986S) than in the three tigecycline-resistant isolates (17296R, 18167R, and 18997) (Fig. 1B) . (Fig. 3) .
When we analyzed the correlation between the expression level of the RND efflux pump adeB gene and H33342 accumulation levels in 120 A. baumannii clinical isolates, we could not find any correlation between fold change level in H33342 accumulation and adeB expression level.
DISCUSSION
Treatment of A. baumannii has become a major concern in hospital settings due to the wide dissemination of multidrug-resistant strains. Overexpression of efflux pumps in A.
baumannii is a common mechanism of multidrug resistance in this nosocomial pathogen [2] .
The H33342 accumulation assay was introduced to estimate the contribution of active efflux pumps to antimicrobial resistance in Salmonella Typhimurium strains [6] . The H33342 accumulation assay was also used to assess the roles of efflux pumps in antimicrobial resistance in A. baumannii clinical isolates [9] .
We utilized the H33342 accumulation assay to assess efflux activity in 120 A. baumannii clinical isolates. In this study, the tigecycline-susceptible and intermediate groups showed relatively higher H33342 accumulation than the tigecycline-resistant group at steady-state. The addition of efflux pump inhibitor CCCP caused a statistically significant increase in H33342 accumulation only in the tigecycline-resistant group. These findings suggest the role of efflux activity in tigecycline resistance based on the following explanations: 1) the strains belonging to the tigecycline-resistant group showed low H33342 accumulation due to effective expulsion of H33342 by active efflux pumps; and 2) increased H33342 accumulation with the addition of CCCP only in the tigecycline-resistant group supports the role of efflux in tigecycline-resistance in that group.
The addition of efflux pump inhibitors (EIs) highlighted the contribution of various efflux pumps to antimicrobial resistance in a variety of bacteria [6, 9, 13] . The addition of PAβN, which inhibits RND transporters, resulted in increased H33342 accumulation, i.e. reduced levels of efflux [9] . Whalen et al. [13] reported that 3,4-dibromopyrrole-2,5-dione, an inhibitor of RND transporters, decreased the minimum inhibitory concentrations (MICs) of various antibiotics, and also increased the intracellular accumulation of H33342 in wild-type, but not in transporter-deficient strains. Opperman et al. [7] reported MBX2319, a novel pyranopyridine inhibitor, had potent activity against RND efflux pumps, and also increased intracellular accumulation of H33342 in wild-type, but not AcrAB-TolC-deficient strains. As described above, the addition of CCCP in A. baumannii AYE reference strain caused a significant increase in H33342 accumulation, suggesting reduced efflux [9] . In that study, the adeB mutant showed increased H33342 accumulation, indicative of reduced activity compared to the parental strain.
Moreover, the addition of CCCP caused a significant increase (P＜0.05) in the level of H33342 accumulation for all 6 clinical isolates tested [9] .
The AdeABC pump is present in approximately 80% (53% to 97%) of A. baumannii clinical strains [2, 14] . Our study showed the presence of the adeB gene in all 120 A. baumannii clinical isolates. Deng et al. [5] reported that the positivity rate of adeB was 84.4% (54/64) for tigecycline-nonsusceptible A. baumannii (TNAB) isolates, and 80% (8/10) for tigecycline-susceptible A.
baumannii (TSAB) isolates. These results were contrary to an earlier result showing that adeABC genes were present in MDR isolates, and not in susceptible isolates [15] .
It is reported that reduced susceptibility to tigecycline appears to be mediated in part by active efflux systems, including We found significant differences in the levels of adeB relative expression between tigecycline-susceptible versus tigecycline-resistant groups (P＜0.05). Therefore, it seems possible that adeB overexpression may contribute to tigecycline resistance.
Deng et al. [5] reported that the mean expression level of the adeB gene in 64 TNAB clinical isolates was 29-fold higher than that in 10 TSAB isolates. Peleg et al. [16] identified 40-fold and 54-fold increases in adeB expression in the two TNAB isolates compared to that in a TSAB isolate. Although we do not know the exact cause of the large differences in adeB expression level between our strains and Deng's, several factors may contribute the differences between them. In contrast to Deng's strains, collected for 1 year, our strains, randomly collected for almost 4 years, may have relatively diverse results, which may explain the difference between them. In addition, we suspect the different features of the test strains, including resistance determinants harbored in each strain, biological state, strain distribution in tested bacteria, characteristics of prevailing or endemic clones in each region or country, the housekeeping gene or control strain used for calibration of adeB relative expression, and the measurement method, condition or equipment etc., may explain the differences in adeB relative expression. Such a difference was also observed in the reported incidence of adeB overexpression.
Yoon et al. [17] The limitation of the present study is that the overall perspective for contribution factor to tigecycline resistance could not be obtained because this study is focused on H33342 accumulation assay and the relative expression of the adeB gene.
Therefore, it may be necessary to undertake further study to closely evaluate their correlation by measuring other relevant factors together. The study may encompass another RND system or a variety of efflux pump genes which may contribute the tigecycline resistance.
In conclusion, our study showed that efflux activity, assessed by H33342 accumulation assay, may contribute to tigecycline-resistance in A. baumannii clinical isolates. However, there was no correlation between the H33342 accumulation ratio and adeB expression level.
